Compounds > phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide
Page last updated: 2024-10-25

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and Acquired-Immune Deficiency Syndrome Dementia Complex

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide has been researched along with Acquired-Immune Deficiency Syndrome Dementia Complex in 1 studies

phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide: cyclic somatostatin octapeptide analog with high affinity & selectivity toward mu opioid receptors

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sagar, V1
Pilakka-Kanthikeel, S1
Atluri, VS1
Ding, H1
Arias, AY1
Jayant, RD1
Kaushik, A1
Nair, M1

Other Studies

1 other study available for phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide and Acquired-Immune Deficiency Syndrome Dementia Complex

ArticleYear
Therapeutical Neurotargeting via Magnetic Nanocarrier: Implications to Opiate-Induced Neuropathogenesis and NeuroAIDS.
    Journal of biomedical nanotechnology, 2015, Volume: 11, Issue:10

    Topics: AIDS Dementia Complex; Apoptosis; Cell Line; Diffusion; Drug Interactions; Humans; Magnetite Nanopar

2015